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Abstract 
Purpose: To evaluate the daily values and trends over time of relevant clinical, ventilatory and laboratory parameters 
during the intensive care unit (ICU) stay and their association with outcome in critically ill patients with coronavirus 
disease 19 (COVID-19).
Methods: In this retrospective–prospective multicentric study, we enrolled COVID-19 patients admitted to Italian 
ICUs from February 22 to May 31, 2020. Clinical data were daily recorded. The time course of 18 clinical parameters 
was evaluated by a polynomial maximum likelihood multilevel linear regression model, while a full joint modeling 
was fit to study the association with ICU outcome.
Results: 1260 consecutive critically ill patients with COVID-19 admitted in 24 ICUs were enrolled. 78% were male with 
a median age of 63 [55–69] years. At ICU admission, the median ratio of arterial oxygen partial pressure to fractional 
inspired oxygen  (PaO2/FiO2) was 122 [89–175] mmHg. 79% of patients underwent invasive mechanical ventilation. 
The overall mortality was 34%. Both the daily values and trends of respiratory system compliance,  PaO2/FiO2, driving 
pressure, arterial carbon dioxide partial pressure, creatinine, C-reactive protein, ferritin, neutrophil, neutrophil–lympho-
cyte ratio, and platelets were associated with survival, while for lactate, pH, bilirubin, lymphocyte, and urea only the 
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The coronavirus disease 2019 (COVID-19) was firstly 
diagnosed in December 2019 in Wuhan (China) and then 
quickly evolved into a pandemic.
The clinical spectrum of COVID-19 ranges from an 
asymptomatic condition to a severe and critical disease 
[1].
Multicentric case series show that between 5 and 32% 
of the patients hospitalized for COVID-19 need inten-
sive care unit (ICU) admission [2–5], mainly for acute 
hypoxemic respiratory failure. Indeed, acute respiratory 
distress syndrome (ARDS) is diagnosed in 40–96% of the 
ICU patients [2, 3, 6–8] and 30–88% of them need inva-
sive mechanical ventilation (IMV) [1, 4, 6, 8, 9]. Most 
ICU patients are males affected by obesity, hypertension, 
cardiovascular diseases, and diabetes [2, 4–8].
The ICU mortality reported ranges from 16 to 78% [3, 
6–10] according to patient and healthcare system char-
acteristics and the percentage of patients still in ICU at 
the end of the follow-up. Notably, the ICU mortality of 
patients receiving IMV is consistently higher, reaching 
values up to 88% [11].
To date, few large multicentric studies have analyzed 
the clinical and laboratory parameters at ICU admission 
as independent predictors for mortality of critically ill 
patients [8, 12], showing significant variability among the 
different series. Our group [5] showed in a large cohort 
of patients that older age, male gender, history of chronic 
pulmonary disease, and the need for IMV are independ-
ent predictors for ICU mortality.
Since critically ill patients with COVID-19 usually 
require prolonged IMV and ICU stay [5], we hypoth-
esized that the temporal trends of the clinical and labora-
tory parameters could predict ICU outcomes even more 
accurately than values at the single point of admission. 
Indeed, a recently published study on mechanically ven-
tilated patients with COVID-19 showed the importance 
of analyzing longitudinal data to assess patient prognosis 
more accurately [13].
Based on available data regarding the target organs of 
COVID-19, we analyzed the trends of clinical parameters 
reflecting the cardiac, pulmonary, kidney, liver, coagula-
tion function, and inflammatory response.
daily values were associated with survival. The trends of  PaO2/FiO2, respiratory system compliance, driving pressure, 
creatinine, ferritin, and C-reactive protein showed a higher association with survival compared to the daily values.
Conclusion: Daily values or trends over time of parameters associated with acute organ dysfunction, acid–base 
derangement, coagulation impairment, or systemic inflammation were associated with patient survival.
Keywords: COVID-19, Intensive care unit, Mortality, Predictors, Time course, Longitudinal models
Take‑home message 
Reported mortality of critically ill patients suffering from COVID-19 
is consistently high. The trends over the entire ICU stay of driving 
pressure, compliance of respiratory system, creatinine, C-reactive 
protein, and ferritin were more predictive of mortality compared 
with the single daily values.
The present large multicentric study evaluates the 
trends over time of relevant clinical and laboratory 
parameters and ventilator settings during the entire ICU 
stay and their association with outcome in critically ill 
patients with COVID-19 admitted to 24 Italian ICUs 
during the first three months of the pandemic.
Materials and methods
Study design and population
A COVID-19 retrospective–prospective multicen-
tric registry was set up at the end of February 2020, at 
the beginning of the pandemic, including most ICUs in 
Northern Italy. The registry was approved by the institu-
tional review board of each hospital and was registered 
on clinicaltrials.gov (NCT04388670).
For this study, all patients with laboratory-confirmed 
SARS-CoV-2 infection admitted to the ICU of the partici-
pant institutions (see Electronic Supplementary Material 
[ESM] for the complete list of ICUs) from February 22, 2020, 
to May 31, 2020, were included in the present study. The Eth-
ics Committee waived the consent for the retrospective part 
of the study, while written informed consent or deferred con-
sent was obtained according to the regulations of each par-
ticipating center for the prospective part of the study.
Laboratory confirmation for SARS-CoV-2 infection 
was obtained by real-time reverse transcriptase-polymer-
ase chain reaction (RT-PCR) assay on nasal and pharyn-
geal swabs and, when clinically indicated, also on lower 
respiratory airway aspirate.
Data collection
Clinical patient data were daily recorded on an electronic 
database (REDCap, Research Electronic Data Capture; 
Vanderbilt University, Nashville, TN, USA) by one or more 
trained investigators in each center. Demographics data 
(age, sex, pre-existing comorbidities, chronic medications, 
date of symptoms onset) were recorded at ICU admission.
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At ICU admission and then daily during the ICU stay, 
the following information was collected: mode of res-
piratory support (oxygen mask, non-invasive mechanical 
ventilation, invasive mechanical ventilation); ventilator 
settings and respiratory parameters (mode of ventilation, 
 FiO2, positive end expiratory pressure [PEEP], respiratory 
rate, tidal volume, peak pressure, plateau pressure, driv-
ing pressure, compliance of respiratory system  [CRS], 
the arterial partial pressure of oxygen  [PaO2], the 
arterial partial pressure of carbon dioxide  [PaCO2], 
 PaO2/FiO2); medications (neuromuscular blocking 
agents, antibiotics, antivirals, steroids, anticoagulative 
drugs, immunosuppressive drugs); prone positioning, 
Table 1 Patients’ characteristics at ICU admission, respiratory and hemodynamic parameters, blood tests, and univariate 
risk factors for outcome
HR hazard ratio, CI confidence interval, BMI body mass index, SOFA sequential organfailure assessment, FiO2 fractional inspired oxygen, PEEP positive end expiratory 
pressure, PaO2/FiO2 ratio of arterial oxygen partial pressure, PaO2arterial oxygen partial pressure, PaCO2 arterial carbon dioxide partial pressure, LDH lactate 




(N = 834, 66.19%)
Death
(N = 426, 33.81%)
P value HR (95% CI)
Demographics
 Age (years) 63 [55–69] (N = 1259) 60 [53–67] (N = 833) 67 [62–73] (N = 426)  < 0.001 1.060 (1.048–1.071)
 Male (n) 979 (77.70%) 640 (76.64%) 339 (79.58%) 0.444 1.097 (0.865–1.390)
 Female (n) 281 (22.30%) 194 (23.26%) 87 (20.42%)
 BMI (kg/m2) 28 [25–31] (N = 1115) 28 [25–31] (N = 749) 28 [25–31] (N = 366) 0.308 1.009 (0.992–1.027)
Clinical parameters
 SOFA score 4 [3–5] (N = 1192) 4 [3, 4] (N = 794) 4 [3–5] (N = 398)  < 0.001 1.206 (1.188–1.336)
 Temperature (°C) 37.0 [36.3–37.7] (N = 1132) 37.0 [36.4–37.8] (N = 754) 36.9 [36.1–37.6] (N = 378) 0.008 0.874 (0.791–0.965)
  FiO2 (%) 70 [60–85] (N = 1203) 60 [50–80] (N = 804) 70 [60–90] (N = 399) 0.032 1.006 (1.000–1.011)
 PEEP  (cmH2O) 12 [10–14] (N = 1047) 12 [10–14] (N = 699) 12 [10–15] (N = 348) 0.206 1.026 (0.986–1.067)
  PaO2/FiO2 (mmHg) 122 [89–175] (N = 1166) 128 [93–186] (N = 780) 107 [81–152] (N = 386) 0.004 0.998 (0.996–0.999)
 pH 7.41 [7.33–7.46] (N = 1181) 7.42 [7.35–7.47] (N = 791) 7.36 [7.29–7.44] (N = 390)  < 0.001 0.045 (0.017–0.114)
  PaO2 (mmHg) 80 [66–102] (N = 1187) 81 [67–104] (N = 795) 77 [64–100] (N = 392) 0.066 0.997 (0.995–1.000)
  PaCO2 (mmHg) 42 [36–51] (N = 1176) 41 [35–49] (N = 788) 44 [37–55] (N = 388) 0.001 1.012 (1.005–1.019)
 Lactate (mEq/L) 1.2 [0.9–1.6] (N = 865) 1.2 [0.9–1.5] (N = 566) 1.3 [1.0–1.8] (N = 299)  < 0.001 1.173 (1.113–1.236)
 Heart rate (bpm) 82 [71–95] (N = 1140) 80 [71–94] (N = 759) 85 [71–97] (N = 381) 0.464 1.002 (0.997–1.007)
 Mean arterial pressure (mmHg) 85 [75–95] (N = 1144) 87 [77–97] (N = 759) 80 [70–93] (N = 385)  < 0.001 0.988 (0.982–0.995)
 Creatinine (mg/dL) 0.89 [0.70–1.11] (N = 1155) 0.84 [0.66–1.04] (N = 771) 0.97 [0.76–1.38] (N = 384)  < 0.001 1.152 (1.092–1.216)
 Urea (mg/dL) 45 [32–69] (N = 1076) 40 [29–60] (N = 720) 59 [41–91] (N = 356)  < 0.001 1.009 (1.007–1.011)
 White blood cells  (103/μL) 8.7 [6.2–12.0] (N = 1161) 8.4 [6.1–11.6] (N = 780) 9.2 [6.4–12.9] (N = 381) 0.032 1.009 (1.001–1.017)
 Neutrophils  (103/μL) 7.1 [5.0–10.5] (N = 937) 6.9 [4.9–9.9] (N = 632) 8.0 [5.4–11.6] (N = 305) 0.172 1.018 (0.992–1.044)
 Lymphocytes  (103/μL) 0.7 [0.5–1.0] (N = 868) 0.7 [0.5–1.0] (N = 586) 0.6 [0.4–1.0] (N = 282) 0.174 0.822 (0.620–1.091)
 Neutrophil–Lymphocyte Ratio 10.8 [6.6–18.2] (N = 854) 9.8 [6.5–16.6] (N = 576) 13.6 [7.2–21.7] (N = 278) 0.522 1.001 (0.998–1.004)
 Platelets  (103/mm3) 235 [177–309] (N = 1162) 246 [185–317] (N = 779) 218 [159–292] (N = 383)  < 0.001 0.998 (0.997–0.999)
 Bilirubin tot (mg/dL) 0.7 [0.5–1.0] (N = 1071) 0.7 [0.5–1] (N = 723) 0.7 [0.5–1.1] (N = 348) 0.009 1.157 (1.038–1.290)
 C-reactive protein (mg/L) 13.4 [5.3–22.3] (N = 1033) 13.3 [5.3–20.8] (N = 693) 13.7 [5.6–24.6] (N = 340) 0.880 1.000 (0.995–1.004)
 Procalcitonin (ng/mL) 0.4 [0.2–1.2] (N = 661) 0.3 [0.2–1.0] (N = 439) 0.5 [0.2–1.7] (N = 222) 0.136 1.014 (0.996–1.033)
 LDH (U/L) 475 [359–639] (N = 964) 458 [348–605] (N = 651) 509 [391–710] (N = 313)  < 0.001 1.001 (1.000–1.001)
 AST (U/L) 44 [30–66] (N = 619) 44 [30–65] (N = 409) 45 [29–68] (N = 210) 0.008 1.003 (1.001–1.005)
 ALT (U/L) 39 [25–63] (N = 763) 40 [26–66] (N = 506) 38 [24–57] (N = 257) 0.705 1.000 (0.998–1.002)
 INR 1.2 [1.1–1.3] (N = 729) 1.2 [1.1–1.3] (N = 483) 1.2 [1.1–1.3] (N = 246) 0.002 1.878 (1.254–2.811)
 Albumin (g/dL) 2.9 [2.6–3.1] (N = 488) 3 [2.6–3.2] (N = 337) 2.8 [2.5–3.0] (N = 151) 0.030 0.679 (0.479–0.964)
 Glucose (mg/dL) 128 [108–171] (N = 694) 123 [106–162] (N = 457) 141 [112–184] (N = 237) 0.020 1.002 (1.000–1.004)
 Fibrinogen (mg/dL) 631 [485–747] (N = 533) 636 [506–753] (N = 369) 607 [425–740] (N = 164) 0.022 0.999 (0.998–1.000)
 D-dimer (ng/mL) 1414 [594–4527] (N = 832) 1156 [515–3545] (N = 582) 2275 [901–6900] (N = 250) 0.148 1.000 (1.000–1.000)
 Ferritin (ng/mL) 1431 [809–2311] (N = 285) 1386 [744–2394] (N = 199) 1457 [1028–2234] (N = 86) 0.116 1.000 (1.000–1.000)
 Troponin T (ng/mL) 8 [0–14] (N = 301) 7 [0–12] (N = 204) 8 [0–23] (N = 97) 0.005 1.000 (1.000–1.001)
 Pro-BNP (ng/L) 277 [112–875] (N = 48) 211 [104–703] (N = 35) 893 [120–1759] (N = 13) 0.007 1.000 (1.000–1.000)
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extracorporeal membrane oxygenation [ECMO], trache-
ostomy, and renal replacement therapy; clinical and labo-
ratory parameters (see  ESM for complete list).
Statistical analysis
No statistical sample size calculation was performed a 
priori, and the sample size was equal to the number of 
patients consecutively treated in the participating ICUs 
during the study period. Continuous variables are pre-
sented as median and interquartile range [IQR], while 
categorical variables are expressed as number of patients 
(percentage). Raw outcome comparisons between survi-
vors and non-survivors were performed with Pearson’s χ2 
test for categorical variables.
The modeling of the impact of longitudinal parameters 
on the survival outcomes was performed in three steps.
First, the association of risk factors with time to death 
in ICU was assessed by univariable and multivariable 
Cox proportional hazards regression models; see sup-
plements. Hazard ratios [HRs] were expressed per unit 
of change in the corresponding variable, if not differ-
ently specified. Time span was days from ICU admission 
to ICU discharge, with death as the event of interest and 
ICU discharge as censoring.
Second, the time course of physiological variables 
during ICU stay according to the patient’s life status at 
discharge was evaluated by a polynomial maximum like-
lihood multilevel linear regression model with a random 
intercept at the patient level and random slope at the 
time level. The longitudinal model was applied, since it 
takes into account the within-patient repeated measure-
ments, differently from the analyses which only average 
the daily values over the ICU stay. Eighteen physiological 
variables were evaluated:  PaO2/FiO2,  CRS, driving pres-
sure, tidal volume on predicted body weight [TV/PBW], 
pH, bilirubin, creatinine, D-dimer, ferritin, lactate, 
C-reactive protein, urea,  PaCO2, platelets, fibrinogen, 
neutrophils, lymphocytes, and neutrophils–lymphocytes 
ratio. Each model included one of the preovious param-
eters, as a dependent variable, while time and patient’s 
clinical outcome were considered independent variables. 
The exponential power of time and interaction between 
time and outcome were evaluated according to model-
based likelihood ratio tests.
The analysis was performed in two ways: (1) temporal 
trends were modeled from ICU admission (day 0) up to 
30 days or ICU discharge/death; (2) the time scale started 
from ICU discharge/death (day 0) back to a maximum of 
30 days before (e.g., − 5 corresponds to 5 days before the 
ICU discharge/death).
Third, full joint modeling of each longitudinal parame-
ter with the time-to-death end point was fit, with Weibull 
parametric regression; the covariates for the survival 
components were chosen according to the result of step 
1; for the longitudinal component, only time was used 
as potential predictor, with the same polynomial order 
selected in step 2 was chosen; the longitudinal com-
ponent was linked to the survival component in time-
dependent associations, with daily value, slope, or both 
(the final model choice was based on the Akaike informa-
tion criterion). For daily value, we intended each single 
day value for each variable along the whole ICU course. 
We log-transformed some variables to achieve normal-
ity before fitting the corresponding model. The stjm rou-
tine in Stata was employed [14]. To present effect sizes 
in a metric familiar to clinicians, we exponentiated the 
coefficients (and confidence intervals) estimated by the 
Weibull models, obtaining hazard ratios.
P values < 0.05 were statistically significant. Analyses 
were performed using SAS 9.4 (SAS Institute Inc., Cary, 
NC, USA), StataSE 16.0 (StataCorp LLC), and SigmaPlot 
12.0 (Systat Software Inc., San Jose, CA).
See ESM  for information regarding comorbidities, 
medications, clinical and laboratory parameters, and sta-
tistical analysis.
Results
From February 22, 2020, to May 31, 2020, a total of 
1284 consecutive critically ill patients with laboratory-
confirmed COVID-19 were admitted to the 24 ICUs 
participating in the present study. Data were not avail-
able for 24 patients; thus, data from 1260 patients were 
included in this report.
Table  1 shows demographic and clinical character-
istics at ICU admission. Overall, about 78% were male 
and age was 63 [55–69] years.
At least one comorbidity was reported in 988 patients 
(78%); hypertension was the most common comorbid-
ity (607 [48.2%]), followed by diabetes (228 [18.1%]), 
cardiovascular diseases different from hypertension 
(197 [15.6%]), and pulmonary diseases (100 [7.9%]) 
(ESM Table 1s).
The time intervals from the symptoms’ onset to intuba-
tion and from hospital to ICU admission were 9 [6–12] 
and 3 [1–5] days, respectively (ESM  Table  4s). At ICU 
admission,  PaO2/FiO2 was 122 [89–175] mmHg, while 
PEEP was 12 [10–14]  cmH2O. 707 (56%) patients were 
invasively ventilated at admission (ESM Table 2s), while 
a further 287 patients underwent invasive mechanical 
ventilation during the ICU stay. 84% of patients received 
neuromuscular blocking drugs for 6 [4–10] days, while 
41% was pronated for 2 [1–4] days (ESM  Table  5s and 
Figs.  38s–39s). See ESM for demographic and clinical 
characteristics of intubated and non-intubated patients 
(ESM Tables 2s–4s) and for a list of therapies used during 
the ICU stay (ESM Table 5s).
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The overall ICU mortality was 33.8% (426/1260), while 
among intubated patients it was 38.5% (272/707).
Multiple clinical and laboratory parameters reflecting 
cardiac, pulmonary, kidney, liver, and coagulation func-
tions at ICU admission were associated with mortality at 
univariable analysis (Table 1 and ESM Tables 2s–3s).
Multivariable Cox regression analysis
At multivariable analysis, age (HR = 1.046, 95% CI 
1.031–1.062, P < 0.0001), SOFA score (HR = 1.257, 95% 
CI 1.162–1.360, P < 0.0001), pH (HR = 0.074, 95% CI 
0.021–0.256, P < 0.0001), and lactate (HR = 1.226, 95% 
CI 1.123–1.337, P < 0.0001) at ICU admission were sig-
nificantly associated with mortality. Among comor-
bidities, only diabetes (HR = 1.609, 95% CI 1.189–2.178, 
P = 0.002) showed an association with mortality. See 
ESM for details.
Parameter changes over time and association 
with outcome
Figures  1, 2, and 3 and ESM  36s–37s show the trends 
throughout the ICU stay of 18 relevant parameters, while 
their associations with survival are reported in Table  2. 
Detailed results are reported in the ESM.
After the final models’ choice, the daily value of 15 
parameters and the weekly slope of ten parameters were 
associated with survival. For five parameters  (CRS, driv-
ing pressure, creatinine, ferritin, C-reactive protein), the 
effect size (shown as hazard ratio for ease of interpreta-
tion) of the slope was higher compared to the daily value.
At ICU admission, both  PaO2/FiO2  and  CRS were 
higher in survivors than in non-survivors, while driving 
pressure and  PaCO2 were higher in non-survivors. In 
survivors,  PaO2/FiO2  progressively increased through-
out ICU stay and  CRS slightly decreased following ICU 
admission while it increased towards ICU discharge. 
Both  PaO2/FiO2 and  CRS decreased over the days in non-
survivors. Driving pressure and  PaCO2 increased in non-
survivors throughout the ICU stay, while, in survivors, 
driving pressure remained stable and  PaCO2 decreased 
(Fig. 1).
For   PaO2/FiO2,  PaCO2,  CRS, and driving pressure, both 
the daily values and the slopes were strongly associated 
with survival, with most trends showing higher effect 
(HRs) than daily values (Table 2).
At ICU admission, in survivors, lactate was lower, 
and pH was higher than in non-survivors, while pH 
decreased, and lactate increased in non-survivors during 
the ICU stay (Fig.  2). However, at the joint model anal-
ysis, only the daily values were associated with survival 
(Table 2).
At ICU admission, bilirubin and creatinine were higher 
in non-survivors and increased in non-survivors during 
the days (Fig. 2). The daily values of both these parame-
ters were associated with survival, but only for creatinine 
the slope was strongly associated with survival (Table 2).
Ferritin and C-reactive protein at ICU admission were 
equally elevated in survivors and non-survivors. Both 
continuously decreased over the days only in survivors 
(Fig.  3). Strong association with survival was detected 
for both ferritin and C-reactive protein’s daily values and 
slopes (Table 2).
Neutrophil–lymphocyte ratio was higher in non-sur-
vivors at ICU admission and increased in non-survivors 
during the ICU stay (Fig. 3). Both daily value and slope 
were associated with survival (Table 2).
D-Dimer at ICU admission was higher in non-sur-
vivors than in survivors, then decreased in both groups 
(Fig. 3), but was not shown to be associated with survival 
in joint modeling (Table 2).
Discussion
The present multicentric study describes 1260 critically 
ill patients with COVID-19-associated acute respira-
tory failure consecutively admitted to 24 Italian ICUs 
during the first pandemic wave. This study specifically 
analyzes the trends of clinical, ventilatory and labora-
tory parameters throughout the entire ICU stay and 
their relationship with outcome. The daily values of 15 
parameters associated with acute organ dysfunction 
(lung, liver, kidney), acid–base derangement, coagu-
lation impairment, or systemic inflammation were 
associated with higher patient survival. Ten of these 
parameters showed different slopes between survi-
vors and non-survivors, and the associations with the 
patient outcome of such slopes were stronger than the 
Fig. 1 Time course of physiological variables during ICU stay according to the patient’s outcome life status at discharge obtained by a polynomial 
maximum likelihood multilevel model with a random intercept at the patient level and random slope at the time level (see text for description of 
the model). a and b  PaO2/FiO2; c and d respiratory system compliance; e and f driving pressure; g and h  PaCO2. Dots represent data from the overall 
models, error bars represent 95% confidence interval of the model. Blue color represents patients discharged from ICU, while red color represents 
patients died in ICU. The analysis was performed in two ways: (1) temporal trends were modeled from ICU admission (day 0) up to 30 days or ICU 
discharge/death (left panels a, c, e, g); (2) the time scale was adjusted by subtracting each patient’s ICU discharge/death time (day 0) back to a 
maximum of 30 days (right panels b, d, f, h)
(See figure on next page.)
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Fig. 1 (See legend on previous page.)
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daily value of the same parameters. This finding sup-
ports the common clinical knowledge that the time 
course of relevant variables is more relevant than the 
single daily value.
The majority of the patients included in the study were 
elderly men with hypertension; four out of five received 
mechanical ventilation, about half were treated with res-
cue strategies for refractory hypoxemia, primary prone 
position, and 98% received inotropic or vasoactive drugs 
at least once during ICU stay.
The overall ICU mortality rate was 34%, but increased 
to 38% if considering only the patients undergoing 
mechanical ventilation at ICU admission. These findings 
are consistent with similar European multicenter studies 
[5, 15–20].
In the present study, the factors showing independ-
ent association with worse ICU outcome were older age, 
acid–base derangement (low pH and high lactate), and 
SOFA at ICU admission and diabetes.
We developed a polynomial maximum likelihood 
multilevel regression model and a joint model to com-
pute the association between ICU outcome and the 
daily value and trends of main clinical parameters. Joint 
modeling has the advantage over simpler methods to 
take into account differential missing data of the longi-
tudinal parameter in surviving vs. dead patients (differ-
ential dropout bias). Few authors showed, in critically ill 
patients, that changes in clinical parameters throughout 
the first few days of ICU stay are different between sur-
vivors and non-survivors [21–24]. However, differently 
from a joint model, these studies generally do not take 
into account the within-patient repeated measurement. 
Moreover, we included time backward from ICU dis-
charge to clearly show the parameter trends over the last 
part of the ICU stay.
Furthermore, none of the previously cited studies com-
pared trends to single daily values, to the best of our 
knowledge.
We detected a strong association between mortal-
ity and acute kidney and respiratory impairment and 
activation of systemic inflammation. The effect size of 
creatinine slope on mortality was almost twice that of 
daily value. Similarly, the association between the slope 
of systemic inflammation parameters (i.e., ferritin and 
C-reactive protein) and mortality were also stronger than 
the daily value. The association of neutrophil–lympho-
cyte ratio daily value with survival was instead higher 
than the trend. The slopes of both compliance of the 
respiratory system and  PaO2/FiO2  are associated more 
strongly with mortality than the daily values, although 
a possible effect of therapeutic interventions should be 
taken into account  (e.g., neuromuscular blockade and 
prone positioning).
Even more impressive is the role of driving pressure 
trend as a predictor of mortality. Multiple studies identi-
fied the driving pressure as one of the strongest predic-
tive variables of mortality, but none of them showed the 
superiority of the driving pressure trend compared with 
the single value. In the present study, the driving pressure 
slope had an effect almost four times stronger than the 
single daily value.
We observed an early multiorgan impairment due to 
the COVID-19 disease already at ICU admission, which 
subsequently worsened during the ICU stay, mainly in 
non-survivors. Particularly, most of the parameters, but 
inflammatory markers, were already different between 
survivors and non-survivors at ICU admission. Such 
differences increase throughout the ICU stay,  since the 
parameter time courses show different, or even opposite, 
slopes. Therefore, the daily analysis of parameter trends, 
especially the most divergent, could assist the clinician in 
daily patient management.
Indeed, previous studies reported early differences in 
the temporal changes of laboratory parameters between 
survivors and non-survivors [8, 10] among hospitalized 
not-critically-ill patients with COVID-19.
Therefore, we can speculate that early and timely detec-
tion, possibly before ICU admission, of the more suscep-
tible patients could limit organ injury and anticipate, if 
possible, optimization of the treatments.
Our study has several limitations. First, this is a ret-
rospective–prospective study performed in 24 Italian 
hospitals in 12 different regions during the first wave of 
the COVID-19 pandemic. We cannot exclude high het-
erogeneity among viral load, admission policies and 
care management, also related to differences in the 
(See figure on next page.)
Fig. 2 Time course of physiological variables during ICU stay according to the patient’s outcome life status at discharge obtained by a polynomial 
maximum likelihood multilevel model with a random intercept at the patient level and random slope at the time level (see text for description of 
the model). a and b Lactate; c and d pH; e and f bilirubin; g and h creatinine. Dots represent data from the overall models, error bars represent 95% 
confidence interval of the model. Blue color represents patients discharged from ICU while red color represents patients died in ICU. The analysis 
was performed in two ways: (1) temporal trends were modeled from ICU admission (day 0) up to 30 days or ICU discharge/death (left panels a, c, e, 
g); (2) the time scale was adjusted by subtracting each patient’s ICU discharge/death time (day 0) back to a maximum of 30 days (right panels b, d, 
f, h)
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characteristics, and strain on the healthcare systems and 
in the socioeconomic patient’s status [25]. Second, only 
ICUs interested in this research project joined the study, 
promoting a possible selection bias. Third, many patients 
were treated, during the hospital stay, with several inves-
tigational drugs (hydroxychloroquine, antivirals, steroids, 
tocilizumab, and others) whose effect, in a study of this 
nature, is difficult to evaluate without running into inter-
pretative errors such as survivor bias. Fourth, the daily 
collected data represent the last available data and not 
the average or the worst value of the previous 24 h.
Fifth, although we have established a sound data collec-
tion and quality control (see ESM) and maximal efforts 
have been employed to minimize the amount of miss-
ing data and promote data quality, being a retrospec-
tive, real-data study, no tests were made specifically for 
the study purposes only; thus, some parameters show 
some missing data. Finally, joint modeling requires sev-
eral assumptions, many of which are untestable, as to the 
best association structure, the best covariable selection, 
the fit of the model, and other. Therefore, the choice of 
the model parameters might be considered somewhat 
arbitrary. Besides, model fitting is computationally 
complex, and not all models could mathematically con-
verge. Finally, the interpretation of the coefficient is not 
immediately evident and is difficult to convey, given the 
complex shape of the relationship with time involving 
polynomials. However, we devised our analysis strat-
egy before fitting any models, and we caution against an 
overconfident interpretation of results.
Conclusion
In this population of 1260 critically ill patients with labo-
ratory-confirmed COVID-19 admitted to 24 Italian ICUs 
during the first pandemic wave, the overall mortality was 
34%. The daily values throughout the entire ICU stay of 
clinical and biochemical parameters reflecting acute 
lung, liver, and kidney dysfunction, acid–base derange-
ment, coagulation impairment, and systemic inflamma-
tion were indicative of subsequent patient survival. The 
temporal trends of driving pressure, compliance of res-
piratory system, creatinine, C-reactive protein and ferri-
tin were more predictive of mortality compared with the 
single daily values.
Fig. 3 Time course of physiological variables during ICU stay according to the patient’s outcome life status at discharge obtained by a polynomial 
maximum likelihood multilevel model with a random intercept at the patient level and random slope at the time level (see text for description of 
the model). a and b Ferritin; c and d neutrophil–lymphocyte ratio; e and f C-reactive protein;  g and h D-Dimer. Dots represent data from the overall 
models, and error bars represent 95% confidence interval of the model. Blue color represents patients discharged from ICU, while red color repre-
sents patients died in ICU. The analysis was performed in two ways: (1) temporal trends were modeled from ICU admission (day 0) up to 30 days or 
ICU discharge/death (left panels a, c, e, g); (2) the time scale was adjusted by subtracting each patient’s ICU discharge/death time (day 0) back to a 
maximum of 30 days (right panels b, d, f, h)
(See figure on next page.)
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